---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-338019"
form_type: "8-K"
ticker: "XENE"
cik: "0001582313"
company_name: "Xenon Pharmaceuticals Inc."
filed_at: "2026-08-06T20:11:40+00:00"
generated_at: "2026-08-06T20:15:51.647762+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Xenon Q2 net loss $110.7M; NDA for azetukalner on track for Q3 2026

## Summary
- Net loss of $110.7M in Q2 2026 vs $84.7M in Q2 2025; R&D expenses rose to $99.2M.
- Cash and securities $1.245B as of June 30, 2026; cash runway into 2029.
- NDA submission for azetukalner in FOS remains on track for Q3 2026 after pre-NDA meeting with FDA.
- Phase 3 X-NOVA2 topline data in MDD expected H1 2027; X-TOLE3 and X-ACKT enrollment ongoing.
- Phase 1 studies for XEN1701, XEN1720 (NaV1.7) and XEN1120 (KV7) expected to complete H2 2026.

## SEC filing metadata
- accession: 0001193125-26-338019
- form_type: 8-K
- ticker: XENE
- cik: 0001582313
- company_name: Xenon Pharmaceuticals Inc.
- filed_at: 2026-08-06T20:11:40+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582313/000119312526338019/0001193125-26-338019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582313/000119312526338019/xene-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-338019
- JSON: https://secwatch.observer/filing/0001193125-26-338019.json
- Plain text: https://secwatch.observer/filing/0001193125-26-338019.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.